Clinical management, antifungal susceptibility, and predictors of 28-day mortality in Candidozyma auris candidemia: a single-center cohort study.

Candidozyma auris candidemia causes 41% 28-day mortality in critically ill patients, with high resistance to fluconazole and significant impact from comorbidities and organ failure.

• Why it matters: Understanding factors influencing mortality and resistance patterns is crucial for improving treatment outcomes and infection control in healthcare settings.
• What they did: A retrospective cohort of 108 adult patients was analyzed, focusing on clinical management, antifungal susceptibility, and predictors of 28-day mortality, including comorbidities and organ dysfunction scores.
• The result: Higher Charlson Comorbidity Index and SOFA scores independently predicted mortality, while resistance to fluconazole was prevalent, emphasizing the importance of local resistance monitoring and early high-risk patient identification.